CD24 Ala/Val polymorphism and multiple sclerosis

J Neuroimmunol. 2006 Jun;175(1-2):200-2. doi: 10.1016/j.jneuroim.2006.03.009. Epub 2006 May 2.

Abstract

CD24 is expressed on a broad range of cells in the immune and central nervous systems and appears to be required for development of experimental autoimmune encephalomyelitis in mice. Association of a CD24 Ala/Val coding polymorphism with susceptibility to and progression of multiple sclerosis was recently reported. We typed this coding polymorphism in a combined cohort of 1,180 cases and 1,168 unrelated and family-based controls from Belgium and the UK, but were unable to confirm either association. Since the CD24 gene is part of a segmental duplication, special care is required for the identification and genotyping of single nucleotide polymorphisms.

Publication types

  • Clinical Trial, Phase II
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alanine / genetics*
  • CD24 Antigen / genetics*
  • Chemotaxis, Leukocyte / drug effects
  • Chemotaxis, Leukocyte / immunology
  • Double-Blind Method
  • Female
  • Humans
  • Longitudinal Studies
  • Male
  • Middle Aged
  • Mitoxantrone / therapeutic use
  • Multiple Sclerosis, Chronic Progressive / drug therapy
  • Multiple Sclerosis, Chronic Progressive / genetics*
  • Multiple Sclerosis, Chronic Progressive / pathology
  • Polymorphism, Single Nucleotide*
  • Receptors, Chemokine / biosynthesis
  • Valine / genetics*

Substances

  • CD24 Antigen
  • Receptors, Chemokine
  • Mitoxantrone
  • Valine
  • Alanine